The cutting edge of aging science isn't about curing death; it's about extending the productive, high-earning years for the elite. Unpacking the true agenda behind longevity research.
Forget the hype. Analyzing MIT's latest 'Breakthrough Technologies' reveals who truly funds innovation and where the next regulatory battlegrounds lie in the world of advanced technology.
Beyond the headlines of new fungal compounds and golden sharks, the real story in 'this week in science' is about biotech hype vs. clinical reality.
Daisy Genomics just snagged $2.5M for precision medicine. But this small raise masks a brutal truth about early-stage biotech funding and AI integration.
New Alzheimer's breakthroughs in mice spark hope, but this 'memory restoration' hides a critical flaw: the translational gap.
The massive influx of private money into academic AI research signals a critical power shift. Who truly controls the future of artificial intelligence?
Guardant Health's strong Q3 performance masks a brutal reality: the race for **liquid biopsy** dominance is about to get bloodier, threatening current **healthcare technology** valuations.
Frederick, MD, is dropping a new biotech bombshell. Forget the press release; we analyze who truly benefits from this disruptive technology.